Innoviva (INVA) Liabilities and Shareholders Equity (2010 - 2026)
Innoviva (INVA) posted Liabilities and Shareholders Equity of $1.8 billion for Q1 2026, up 12.32% on a QoQ basis from $1.6 billion in Q4 2025, and up 46.41% year-over-year from $1.3 billion in Q1 2025.
Innoviva (INVA) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Innoviva's Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $1.8 billion for Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 46.41% year-over-year to $1.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.2 billion (up 24.39% YoY) and the FY2025 annual result came in at $1.6 billion, up 25.68% from the prior year.
- Liabilities and Shareholders Equity was $1.8 billion for Q1 2026 at Innoviva, up from $1.6 billion in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $1.8 billion in Q1 2026 and bottomed at $1.1 billion in Q1 2022.
- A 5-year average of $1.3 billion and a median of $1.2 billion in 2023 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 49.65% — and 2023, when it decreased 10.51%.
- Innoviva's Liabilities and Shareholders Equity stood at $1.2 billion in 2022, then gained by 0.98% to $1.2 billion in 2023, then gained by 4.63% to $1.3 billion in 2024, then increased by 25.68% to $1.6 billion in 2025, then advanced by 12.32% to $1.8 billion in 2026.
- Business Quant data shows INVA's Liabilities and Shareholders Equity at $1.8 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.4 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | Innoviva | 1.57 Bn | 969.11 Mn | 75.83 Mn | 1.84 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.84 Bn |
| Dec 31, 2025 | 1.64 Bn |
| Sep 30, 2025 | 1.43 Bn |
| Jun 30, 2025 | 1.33 Bn |
| Mar 31, 2025 | 1.25 Bn |
| Dec 31, 2024 | 1.30 Bn |
| Sep 30, 2024 | 1.23 Bn |
| Jun 30, 2024 | 1.22 Bn |
| Mar 31, 2024 | 1.27 Bn |
| Dec 31, 2023 | 1.24 Bn |
| Sep 30, 2023 | 1.19 Bn |
| Jun 30, 2023 | 1.12 Bn |
| Mar 31, 2023 | 1.13 Bn |
| Dec 31, 2022 | 1.23 Bn |
| Sep 30, 2022 | 1.33 Bn |
| Jun 30, 2022 | 1.14 Bn |
| Mar 31, 2022 | 1.11 Bn |
| Dec 31, 2021 | 926.40 Mn |
| Sep 30, 2021 | 887.24 Mn |
| Jun 30, 2021 | 789.15 Mn |